Donanemab has been linked to a 40% lower risk of progressing from mild cognitive ... This is “just the opening chapter in a new era of molecular therapies for Alzheimer’s disease,” Dr ...

Drugmaker Eli Lilly says that approval of its experimental Alzheimer’s medication donanemab will be delayed beyond the end of March as the US Food and Drug Administration plans to call a last ...

The US Food and Drug Administration on Tuesday approved donanemab, a monoclonal antibody designed to slow the progression of early symptomatic Alzheimer’s disease.

UW has begun treating patients with donanemab, a new Alzheimer’s medication that may slow cognitive decline in people with early-stage disease. advertisement. KIRO Seattle.

Donanemab, which targets the amyloid plaques that build up in the brain of Alzheimer’s patients, has taken an unusually long time to work through the approval process. Shots - Health News ...

The Food and Drug Administration on Tuesday approved the experimental Alzheimer's drug donanemab, which slowed the early stages of the fatal mind-robbing disease in studies. The approval comes ...

The FDA’s approval of three new drugs – donanemab, lecanemab and aducanumab – in just over three years has led some to declare a leap forward in Alzheimer’s disease treatment.

The Food and Drug Administration on Tuesday approved donanemab for treating Alzheimer’s disease, after clinical studies indicated Eli Lilly’s drug could significantly slow cognitive decline ...

An experimental Alzheimer’s medication slowed declines in patients’ ability to think clearly and perform daily tasks by more than a third in a large clinical trial, drugmaker Eli Lilly said ...